Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/31/2003WO2004000819A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
12/31/2003WO2004000817A2 Benzimidazole compounds and their use as estrogen agonists/antagonists
12/31/2003WO2004000816A1 Androgen receptor agonist
12/31/2003WO2004000815A1 Acutumine and acutumine compounds, synthesis and use
12/31/2003WO2004000808A2 N-substituted piperidine derivatives as serotonin receptor agents
12/31/2003WO2004000807A1 Cannabinoid receptor agonists
12/31/2003WO2004000805A1 Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
12/31/2003WO2004000804A1 Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
12/31/2003WO2004000803A1 Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
12/31/2003WO2004000802A2 Scaffolded maleimide clusters for multivalent peptide assembly
12/31/2003WO2004000801A2 Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
12/31/2003WO2004000793A2 Aminoacetonitrile derivatives suitable for controlling parasites
12/31/2003WO2004000790A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003WO2004000789A1 Amide linker peroxisome proliferator activated receptor modulators
12/31/2003WO2004000788A1 Ureido-substituted aniline compounds useful as serine protease inhibitors
12/31/2003WO2004000786A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
12/31/2003WO2004000785A2 Phenyloxyalkanonic acid derivatives as hppar activators
12/31/2003WO2004000783A1 Aminoalkylphenols, methods of using and making the same
12/31/2003WO2004000782A1 Preparation method of valienamine from acarbose and/or acarbose derivatives using trifluoroacetic acid
12/31/2003WO2004000781A2 Nitrooxyderivatives of cyclooxygenase-2 inhibitors
12/31/2003WO2004000762A2 Propionic acid derivatives and their use as hppars activators
12/31/2003WO2004000383A2 Polyacrylates coatings for implantable medical devices
12/31/2003WO2004000372A2 Disinfecting composition, cleaning tablet produced therefrom, and use thereof
12/31/2003WO2004000368A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
12/31/2003WO2004000365A1 Drug transport and delivery system
12/31/2003WO2004000364A1 Preparation containing polydimethylsiloxane for nails, cartilage, bone joint, muscle and tendon disorders
12/31/2003WO2004000362A1 Process for producing block copolymer/drug composite
12/31/2003WO2004000361A1 Metastable pharmaceutical compositions
12/31/2003WO2004000360A1 Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis
12/31/2003WO2004000359A1 Topical pharmaceutical composition comprising skin penetration enhancers for the treatment of warts
12/31/2003WO2004000358A1 Transdermal drug delivery system
12/31/2003WO2004000357A1 Potentiating the antipyretic action of nonopioid analgesic
12/31/2003WO2004000356A1 Medicinal composition containing diuretic and peroxisome proliferator-activated receptor (ppar) ϝ actiavtor
12/31/2003WO2004000355A1 Combination treatment for depression and anxiety by nk1 and nk3 antagonists
12/31/2003WO2004000354A2 Method of treating the syndrome of lipodystrophy
12/31/2003WO2004000353A1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs
12/31/2003WO2004000352A1 Therapeutic compound against leishmania infection and use thereof
12/31/2003WO2004000345A1 Preventives/remedies for bone and joint diseases
12/31/2003WO2004000342A1 Use of mixtures of active substances for the production of a medicament against rheumatic arthritis
12/31/2003WO2004000336A1 Avian appeasing pheromones to decrease stress, anxiety and aggressiveness
12/31/2003WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
12/31/2003WO2004000332A1 Anticoagulant composition
12/31/2003WO2004000331A1 Organ arrest, protection, preservation and recovery
12/31/2003WO2004000330A1 Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases
12/31/2003WO2004000329A1 Prophylactic and therapeutic treatment of migraine and migraine-related diseases with macrolide and/or tetracycline compounds and/or gyrase inhibitors
12/31/2003WO2004000327A1 Therapeutic agent for type 2 diabetes
12/31/2003WO2004000326A1 Combination therapy wherein a serotonin reuptake inhibitor is used
12/31/2003WO2004000325A1 Prostaglandin-containing preparation composition for nasal administration
12/31/2003WO2004000324A1 Pharmaceutical compositions for the treatment of diseases related to neurotrophines
12/31/2003WO2004000323A1 Medicinal cephem compound composition for injection
12/31/2003WO2004000322A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000321A1 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
12/31/2003WO2004000320A1 Water-based preparation for eye drop
12/31/2003WO2004000319A1 Antimalarial activities of febrifugine analogues
12/31/2003WO2004000317A1 Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride
12/31/2003WO2004000316A1 Use of mglur5 antagonists for the treatment of gerd
12/31/2003WO2004000315A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators
12/31/2003WO2004000314A1 Methods of using benzothiophenone derivatives to treat cancer or inflammation
12/31/2003WO2004000313A2 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
12/31/2003WO2004000312A2 Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
12/31/2003WO2004000311A2 Pharmaceutical composition comprising calcium channel blockers for the treatment of pain
12/31/2003WO2004000310A1 Medicament for the treatment of the systemic inflammatory response syndrome
12/31/2003WO2004000309A1 The use of benzisoselenazolone compounds against ischemic myocardial damage
12/31/2003WO2004000308A1 Method of photodynamic diagnosis for vascular diseases
12/31/2003WO2004000307A1 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor
12/31/2003WO2004000306A1 Novel antimalarial agent
12/31/2003WO2004000305A1 Composition for the treatment of skin diseases and for improving hair growth
12/31/2003WO2004000304A1 Lignan formulations
12/31/2003WO2004000303A1 Method for therapeutic modality on a patient organism during the cure of parkinson's disease
12/31/2003WO2004000301A1 Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether
12/31/2003WO2004000300A1 Cyclooxygenase-2 inhibitors
12/31/2003WO2004000299A1 Body fat degradation promoters and foods and drinks
12/31/2003WO2004000298A1 Pharmaceutical compositions for the treatment of infections of the respiratory system by pathogenic agents
12/31/2003WO2004000297A1 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
12/31/2003WO2004000296A1 (2s)-2amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
12/31/2003WO2004000295A1 Benzoic acid derivatives as modulators of ppar alpha and gamma
12/31/2003WO2004000294A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
12/31/2003WO2004000293A2 Use of taurine or derivatives thereof for the treatment of alopecia
12/31/2003WO2004000292A1 Composition comprising stabilised choline ascorbate
12/31/2003WO2004000291A1 Topical administration of basic antifungal compositions to treat fungal infections of the nails
12/31/2003WO2004000290A1 Pharmaceutical composition
12/31/2003WO2004000288A1 Fluorosiloxane matrix controlled diffusion drug delivery system
12/31/2003WO2004000286A1 Microcapsules for the delayed, controlled release of perindopril
12/31/2003WO2004000284A1 Pharmaceutical compositions with improved dissolution
12/31/2003WO2004000281A1 Rapidly disintegrating tablet
12/31/2003WO2004000277A1 Resorbable delivery systems for the treatment of cancer
12/31/2003WO2004000275A1 Transdermal aerosol compositions
12/31/2003WO2004000273A1 Oral pharmaceutical forms of liquid drugs having improved bioavailability
12/31/2003WO2004000272A1 Nasal compositions comprising a mucopolysaccharide and propylene glycol
12/31/2003WO2004000271A1 Use of bases for the manufacture of a medicament in the treatment of different forms of inflammatory dermatosis
12/31/2003WO2004000269A1 Short duration depot formulations
12/31/2003WO2004000267A1 Method for modulation of drug release from multiphase implantable or insertable medical devices and a process for manufacturing such devices
12/31/2003WO2004000265A2 Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
12/31/2003WO2004000254A1 Soft solid antiperspirant with cooling and drying effect
12/31/2003WO2004000253A1 Improved pharmaceutical dental formulations
12/31/2003WO2004000245A1 Promoter for uptake of basic amino acid into cell and cosmetic or drug composition
12/31/2003WO2004000237A2 Enhancing treatment of mdr cancer with adenosine a3 antagonists
12/31/2003WO2004000230A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
12/31/2003WO2004000229A2 Treatment of human multiple myeloma by curcumin
12/31/2003WO2004000228A2 Methods for preventing and treating microbial infections by modulating transcription factors
1 ... 5227 5228 5229 5230 5231 5232 5233 5234 5235 5236 5237 5238 5239 5240 5241 5242 5243 5244 5245 5246 5247 ... 7860